Cellect Biotechnology completes proof of concept testing of ApoTainer
Cellect Biotechnology announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer using Cellect's FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products' manufacturing. The ApoTainer is designed to replace highly complex and expensive procedures currently used by laboratories, with a significantly more effective process at a fraction of the time and cost. The company believes the ApoTainer represents a breakthrough in achieving commercial grade scalability with a solution suitable for a wide range of users from large pharma companies interested in cost effective stem cell production through hospitals and clinics to small research laboratories. Pre-clinical proof of concept testing of Cellect's proprietary ApoTainer has shown that the use of FasL-coated magnetic beads significantly increases the active surface allowing a dramatic increase of interactions between the selecting agent and the cells. The testing showed that the prototype increases specific elimination of certain (but not all) of the non-stem cells while full preservation of the number and function of the stem and progenitor cells. Utilizing the ApoTainer, Cellect expects blood stem cell donation to be transplantable within less than 6 hours from donation through a simple process performed at the hospital bedside instead of undergoing a lengthy laboratory procedure in a highly specialized setting. The standard medical procedure for reaching enriched stem cells currently costs tens of thousands of dollars and produces significant adverse effects.